Modality
Degrader
MOA
CDK2i
Target
PARP
Pathway
Complement
WMMS
Development Pipeline
Preclinical
~Mar 2010
→ ~Jun 2011
Phase 1
~Sep 2011
→ ~Dec 2012
Phase 2
~Mar 2013
→ ~Jun 2014
Phase 3
~Sep 2014
→ ~Dec 2015
NDA/BLA
~Mar 2016
→ ~Jun 2017
Approved
Sep 2017
→ Feb 2028
ApprovedCurrent
NCT07857159
1,623 pts·MS
2025-07→2028-02·Completed
NCT03368160
2,075 pts·WM
2020-04→TBD·Completed
NCT04727295
1,424 pts·WM
2017-09→2025-07·Completed
5,122 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2025-07-258mo agoPh3 Readout· WM
2028-02-201.9y awayPh3 Readout· MS
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Approved
Complet…
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2025-07-25 · 8mo ago
WM
Ph3 Readout
2028-02-20 · 1.9y away
MS
Completed|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07857159 | Approved | MS | Completed | 1623 | Safety |
| NCT03368160 | Approved | WM | Completed | 2075 | FEV1 |
| NCT04727295 | Approved | WM | Completed | 1424 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |